**Efficacy and Tolerability of Trandolapril in Mild-to-moderate Hypertension: A Double-blind Comparison with Enalapril**

**JYOTHI R**, **PUNDARIKAKSHA HP**, **SRINIVASA PRABHU NC**, **GIRISH K**, **VASUNDHARA K**

### ABSTRACT

**Objective:** To compare the efficacy and tolerability between trandolapril and enalapril in mild-to-moderate hypertension.

**Material and Methods:** This was a prospective, double-blind, parallel, comparative clinical trial involving 120 patients with mild-to-moderate hypertension. Patients were randomized to receive trandolapril 2-4 mg once-daily and enalapril 5-10 mg once-daily. The participants were followed for eight weeks. **Results:** Both the drugs achieved effective control of blood pressure (BP) at the end of eight weeks. The mean reduction in systolic BP (SBP) was 22.17 mmHg with trandolapril and 21.47 mmHg with enalapril group; the mean reduction of diastolic BP (DBP) was 9.57 mmHg with trandolapril and 11.13 mmHg with enalapril. Adverse events developed in 11 (18.3%) and 12 (20%) patients in trandolapril and enalapril group, respectively. **Conclusion:** The efficacy and tolerability of trandolapril was comparable to enalapril in mild-to-moderate hypertension with minor adverse events.

**Keywords:** Hypertension, ACEIs, trandolapril, enalapril

Hypertension is one of the most prevalent vascular diseases in the world and poses a major public health problem. Angiotensin-converting enzyme inhibitors (ACEIs) are accepted as first-line therapy in the treatment of hypertension and heart failure. The principle antihypertensive effect is through renin-angiotensin-aldosterone (RAA) mechanism. They offer distinct advantages such as preventing or reversing cardiovascular remodeling, diabetic complications, improving endothelial function and also enhancing fibrinolysis. The American Heart Association and American College of Cardiology (AHA/ACC) recommend ACEIs as standard therapy in patients who are at high-risk for cardiovascular morbidity and mortality. In recent years, there has been a rapid growth in the number of ACEIs entering the market. Most have claimed some sort of advantages based on differences in pharmacokinetics, metabolism or tissue ACE binding. Trandolapril is a new non-sulphhydryl lipophilic ACEI. The main pharmacodynamic effects of trandolapril are achieved by reduction in plasma angiotensin-II levels, which leads to a reduction in total peripheral vascular resistance, blood pressure (BP) and decreased sodium and water retention by the kidney. It has an effective long duration of action in the dose of 2-4 mg daily and is well-tolerated with minor adverse events. Few studies were done in Indian population to compare its efficacy and tolerability with other ACEIs. The present study was undertaken to compare the efficacy and tolerability of trandolapril with enalapril in mild-to-moderate essential hypertension.

### MATERIAL AND METHODS

The present study was a randomized, double-blind, parallel, comparative clinical trial carried out in Kempegowda Institute of Medical Sciences Hospital and Research Centre, Bangalore, over a period of one year. The study protocol was approved by the Institutional Ethical Committee, and conducted in accordance with the Declaration of Helsinki. After obtaining written informed consent, 120 patients of either sex in the age group of 20-60 years with...
mild-to-moderate hypertension (sitting diastolic BP [DBP] between 90-110 mmHg) were recruited for the study. Patients who were previously receiving antihypertensive medication were given two weeks’ washout prior to entry into the study. Patients with the following conditions were excluded from the study; pregnant and lactating women, patients with history of drug allergy or intolerance to ACEIs, patients unwilling to comply with the protocol requirement, patients with severe hypertension, patients already on antihypertensive drugs or other medications known to affect the outcome of the study, patients who had participated in other clinical trials in the past one month, patients with history or evidence of renal, hepatic or neurological disease, patients with uncontrolled diabetes and patients with suspected bilateral renal artery stenosis or single kidney. A detailed medical history, clinical examination, anthropometric measurements and baseline laboratory investigations were carried out.

Patients fulfilling the study criteria were randomly assigned to two groups of 60 each to receive either trandolapril 2 mg or enalapril 5 mg. The BP was recorded at baseline, at 2, 4 and 8 weeks. BP was recorded 3 times at each visit after five minutes of rest in a sitting posture. Compliance was monitored by pill count method. Patients were monitored for adverse events throughout the study period.

Laboratory investigations like Hb%, WBC count, blood urea, serum creatinine, lipid profile, serum electrolytes (sodium and potassium), FBS, urine analysis and ECG were done at baseline and at the end of eight weeks. Romhilt-Esters point score system was used to detect left ventricular hypertrophy (LVH) by using ECG.

Data was expressed in percentages and mean ± SD. Student ‘t’ test was used to find the significance of systolic BP (SBP) and DBP between the two groups. ANOVA was used to find the significance of SBP and DBP during the study period within each group.

RESULTS

Out of 120 patients, 64 were men and 56 women. The mean age in trandolapril and enalapril group was 51.21 ± 6.0 and 50.57 ± 6.16 years, respectively. Sixty-eight (56.66%) patients were from urban and 52 (43.33%) from rural area.

The mean SBP at baseline in the trandolapril group was 151.57 ± 7.63 mmHg compared with 151.07 ± 7.14 mmHg in the enalapril group. The mean DBP at baseline in the trandolapril group was 98.40 ± 4.49 mmHg compared with 100.53 ± 5.66 mmHg in the enalapril group (Table 1). There were no significant differences between the two groups with respect to demographic and baseline characteristics.

The most frequent comorbid conditions present in both groups included type 2 diabetes mellitus in 16.66% (n = 20), obesity (body mass index [BMI] ≥25 kg/m²) in 28.33% (n = 34), diabesity in 9.16% (n = 11) and LVH based on ECG changes in 9.16% (n = 11) of patients (Table 2). At the end of two and four weeks, 38% and 75% of the study subjects in trandolapril group and 27% and 58% in the enalapril group achieved reduction in DBP to <90 mmHg and reduction in DBP at four weeks was shown to be significant (p < 0.05). The dose of trandolapril was increased from 2-4 mg in 25% (n = 15) and enalapril from 5-10 mg in 41.7% (n = 25) of patients at the end four weeks in patients who did not show DBP reduction to <90 mmHg with the initial dose.

The mean SBP/DBP in the trandolapril group was 151.57 ± 7.63/98.40 ± 4.49 at baseline, 144.30 ± 7.12/94.27 ± 4.58 after two weeks, 137.13 ± 6.16/91.45 ± 3.02 after four weeks and 129.40 ± 0.81/88.83 ± 1.34 after eight weeks. Mean fall in SBP and DBP was shown to be 22.17 and 9.57 mmHg (Table 3).

<table>
<thead>
<tr>
<th>Table 1. Demographic and Basic Characteristics</th>
</tr>
</thead>
<tbody>
<tr>
<td>Characteristics</td>
</tr>
<tr>
<td>Age (years)</td>
</tr>
<tr>
<td>Sex: Male/Female (N)</td>
</tr>
<tr>
<td>Location: Urban/Rural (N)</td>
</tr>
<tr>
<td>Basal SBP (Mean ± SD) mmHg</td>
</tr>
<tr>
<td>Basal DBP (Mean ± SD) mmHg</td>
</tr>
</tbody>
</table>

N = 60 in each group. Values are mean ± standard deviation (SD).

<table>
<thead>
<tr>
<th>Table 2. Comorbid Conditions in Study Groups</th>
</tr>
</thead>
<tbody>
<tr>
<td>Comorbid conditions</td>
</tr>
<tr>
<td>Type 2 diabetes mellitus</td>
</tr>
<tr>
<td>Obesity</td>
</tr>
<tr>
<td>Diabesity</td>
</tr>
<tr>
<td>LVH</td>
</tr>
</tbody>
</table>

Numbers in parenthesis indicates percentage.
and 9.57 mmHg (Table 3). Mean fall in SBP and DBP was shown to be 21.47 and 11.23 mmHg. There was no significant difference in mean fall in SBP and DBP in both groups.

ECG was recorded in all patients at baseline and at the end of eight weeks. Eleven patients from both groups had pre-existing changes suggestive of LVH. Out of 11, one patient in trandolapril group showed partial reversal of LVH. All laboratory parameters both at baseline and at the end of eight weeks were within normal limits.

Adverse events were encountered in 18.33% (n = 11) and 20% (n = 12) of patients in trandolapril and enalapril group, respectively. Cough (6.6%), headache (3.3%) and myalgia (3.3%) were experienced in the trandolapril group. Giddiness (6.6%), cough (5%), headache (3.3%) and fatigue (3.3%) were seen in the enalapril group (Table 4). The most common adverse event from both groups was cough in 5.8% (n = 7). All the adverse events were mild, transient and did not require any treatment, discontinuation of medication or withdrawal from the study.

**DISCUSSION**

In the present study, reduction in DBP to <90 mmHg was achieved in 75% of patients who received trandolapril 2 mg and in 58% of those who received enalapril 5 mg for four weeks. All patients achieved target DBP reduction by the end of eight weeks after doubling of dose in both groups. Similar findings were observed in studies carried out by Shankar et al,\(^1\) they had shown that 98.4% patients with trandolapril and 93% with enalapril achieved target DBP reduction at the end of eight weeks. In the present study, mean reduction in SBP and DBP was 22.17 and 9.57 mmHg in trandolapril group.

In two noncomparative trials, where trandolapril was administered for a period of two weeks to 12 months in mild-to-moderate hypertension, mean reduction in SBP ranged from 7 to 31 mmHg and in DBP from 8 to 20 mmHg.\(^12,13\) Many controlled clinical trials have found that trandolapril produces clinically significant BP reduction and achieves target BP level in patients with hypertension.\(^14,15\) The observations reflect that trandolapril is equally efficacious and comparable to enalapril and that trandolapril offers a satisfactory approach for reduction of BP in mild-to-moderate hypertension. In this study, one patient from trandolapril group with LVH showed partial reversal.

Schmieder\(^16\) observed in a meta-analysis that ACEIs brought about early and significant decrease in LVH mass and wall thickness in 13% of patients with a mean duration of 25 weeks. In this regard, there is a need to conduct further studies to confirm the observation.

In the present study, cough was the common adverse event in both the groups, which accounted for 6.66% and 5% of patients, respectively. Many studies have proposed that bradykinin and substance P were responsible for the production of cough.\(^17,18\) In many studies, it was observed that the incidence of cough ranged from 2.3 to 39.1% and drug withdrawal was minimal.\(^19,21\) In the present study, we observed that cough was mild, transient and did not require discontinuation of medication or withdrawal from the study.

---

**Table 3. Changes in SBP and DBP in Trandolapril and Enalapril Groups during the Study**

<table>
<thead>
<tr>
<th>Visits</th>
<th>Trandolapril</th>
<th>Enalapril</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>SBP</td>
<td>DBP</td>
</tr>
<tr>
<td>Basal</td>
<td>151.57 ± 7.63</td>
<td>98.40 ± 4.49</td>
</tr>
<tr>
<td>2 weeks</td>
<td>144.30 ± 7.12</td>
<td>94.27 ± 4.58</td>
</tr>
<tr>
<td>4 weeks</td>
<td>137.13 ± 6.16</td>
<td>91.45 ± 3.02</td>
</tr>
<tr>
<td>8 weeks</td>
<td>129.40 ± 1.12</td>
<td>88.83 ± 1.34</td>
</tr>
</tbody>
</table>

Values are mean ± standard deviation (SD). No statistical significance between two groups.

**Table 4. Adverse Events in the Study Group**

<table>
<thead>
<tr>
<th>Adverse events</th>
<th>Trandolapril</th>
<th>Enalapril</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cough</td>
<td>4 (6.66)</td>
<td>3 (5)</td>
</tr>
<tr>
<td>Giddiness</td>
<td>1 (1.66)</td>
<td>4 (6.66)</td>
</tr>
<tr>
<td>Headache</td>
<td>2 (3.33)</td>
<td>2 (3.33)</td>
</tr>
<tr>
<td>Fatigue</td>
<td>1 (1.66)</td>
<td>2 (3.33)</td>
</tr>
<tr>
<td>Myalgia</td>
<td>2 (3.33)</td>
<td>1 (1.66)</td>
</tr>
<tr>
<td>Abdominal discomfort</td>
<td>1 (1.66)</td>
<td>0 (0)</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>11 (18.33)</strong></td>
<td><strong>12 (20)</strong></td>
</tr>
</tbody>
</table>

Numbers in parenthesis indicates percentage.
DISTURBED
BY
SIDE EFFECTS
OF HIGH
ELEMENTAL IRON?

NAUSEA

CONSTIPATION

G.I DISTURBANCE

IRON OVERLOAD

℞ DEXORANGE®

(Ferric Ammonium Citrate + Cyanocobalamin + Folic Acid) Syrup
(with Zinc advantage) Capsule

The Most Tolerated Iron Supplement
CONCLUSION

The present study suggests that the efficacy and tolerability of trandolapril were comparable to enalapril in mild-to-moderate hypertension. Both drugs effectively controlled SBP and DBP at the end of eight weeks and were well-tolerated with few minor adverse events.

Acknowledgment

Authors are thankful to M/s Hetero Drugs, Hyderabad for providing the clinical supplies.

REFERENCES

The Future is Predictable... (тайм)

The Future is ALARMING!!!

DATE: 14TH NOV, 2030 A.D.
LOCATION: INDIA (THE DIABETIC CAPITAL OF THE WORLD)
POPULATION: 1,100 CRORES
DIABETIC POPULATION: 289 CRORES & STILL COUNTING...

Let’s challenge the future...
Let’s control the rising incidences of diabetes
With the comprehensive range of products...

GLYCIPHAGE®
(Metformin 250 mg Tablets, 500 mg & 850 mg Press Tablets)

GLYCIPHAGE® SR
(Metformin 500mg & 1gm Sustained Release Tablets)

GLYCIPHAGE® G²
(Metformin SR 500mg + Glimperide 1mg / 2mg Tablets)

GLYCIPHAGE® G² FORTE
(Metformin SR 1000mg + Glimperide 1mg / 2mg Tablets)

GLYCIPHAGE® P²
(Metformin SR 500mg + Pioglitazone 15mg / 30mg Tablets)

GLYCIPHAGE® PG²
(Metformin 500 mg SR + Pioglitazone 15 mg + Glimperide 1mg/2mg)

Voliphage™
(Voglibose 0.2 mg / 0.3 mg Tablets)

Voliphage-M™
(Metformin S.R. 500 mg + Voglibose 6.2 mg / 0.3 mg Tablets)

DIABETIX
A Division of FRANCO-INDIAN PHARMACEUTICALS PVT. LTD.

DIAVIT™ Plus